tiprankstipranks
Trending News
More News >

Hepion Pharmaceuticals Sells Rencofilstat Patent Assets

Story Highlights
Hepion Pharmaceuticals Sells Rencofilstat Patent Assets

Don’t Miss TipRanks’ Half-Year Sale

Hepion Pharmaceuticals ( (HEPA) ) just unveiled an update.

On May 26, 2025, Hepion Pharmaceuticals entered into an agreement with Panetta Partners Limited for the sale of all patent assets and related data for Rencofilstat. The agreement includes contingent value rights for Hepion’s stockholders, with potential payments tied to regulatory approval and sales milestones of the drug.

More about Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on drug development and clinical trials.

Average Trading Volume: 4,824,820

Technical Sentiment Signal: Strong Sell

Current Market Cap: $713.5K

For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1